• +55 (48) 3261-2856
  • contato@cienp.org.br

Categoria: Sem categoria

Secretário de Ciência, Tecnologia e Insumos Estratégicos do Ministério da Saúde visita o CIEnP

No dia 12 de agosto de 2017, o Secretário de Ciência, Tecnologia e Insumos Estratégicos do Ministério da Saúde, Dr. Marco Fireman esteve durante todo o dia em vista ao CIEnP. A visita contou também com a presença da diretora do Departamento de Ciência e Tecnologia (DECIT) Dra. Camile G. Sachetti além de vários técnicos daquele ministério.. O Secretário e sua comitiva tiveram a oportunidade de conhecer todas as instalações do CIEnP, incluindo seus 24 laboratórios e o biotério. Além…

Drug pipeline 2Q17

Laura DeFrancesco FDA approvals continue the upward trend noted in the first quarter, with the registration of the first deuterated compound, a new small- molecule drug for amyotrophic lateral sclerosis (ALS) and acceler-  ated approval of Imfinzi, a checkpoint inhibitor for use in bladder cancer. A slew of drugs gained breakthrough therapy designation (Supplementary Table 1). The first approved gene therapy Glybera was axed for economic reasons; two biosimilars ran into trouble at the FDA. Fonte: NATURE BIOTECHNOLOGY VOLUME 35 NUMBER 8 AUGUST 2017 Para…

First eczema biologic debuts but price could restrict use

The US Food and Drug Administration has approved the first biologic therapy for atopic dermatitis, the itchy skin condition better known as eczema. The drug is a human monoclonal antibody called Dupixent (dupilumab) that targets the interleukin-4 (IL-4) receptor alpha subunit, thereby blocking the signaling of two pro-inflammatory cytokines—IL-4 and IL-13—both of which are key mediators of the T helper type 2 (TH2) immune response, thought to be the main driver of the disease… Para acessar a publicação na íntegra clique  aqui Fonte: NATURE BIOTECHNOLOGY VOLUME 35 NUMBER 5…

Genentech’s Ocrevus heralds new chapter in MS treatment

The widely anticipated FDA approval of Genentech’s CD20-targeting antibody Ocrevus (ocrelizumab) for treating both relapsing and primary progressive forms of multiple sclerosis (MS), on March 28, marks the beginning of a new era in MS therapy… Para acessar a publicação na íntegra clique  aqui…

Astex shapes CDK4/6 inhibitor for approval

Kisqali (ribociclib), a frontline treatment for metastatic breast cancer developed by Basel, Switzerland–based Novartis, won approval from the US Food and Drug Administration (FDA)… Para acessar a publicação na íntegra clique  aqui Fonte: 396 VOLUME 35 NUMBER 5 MAY 2017 NATURE BIOTECHNOLOGY…

FDA approves PARP inhibitor for ovarian cancer

Months ahead of schedule, the US Food and Drug Administration approved… Para acessar a publicação na íntegra clique  aqui Fonte: 398 VOLUME 35 NUMBER 5 MAY 2017 NATURE BIOTECHNOLOGY…

Genomics pioneer gets its first drug

The US Food and Drug Administration’s February 28 approval of Xermelo (telotristat) marks the first drug successfully commercialized by Lexicon Pharmaceuticals. Founded in 1995 to pursue new target discovery, Lexicon, based in The Woodlands, Texas, built an extensive library of novel targets using a functional genomics approach and mouse knockout technology… Para acessar a publicação na íntegra clique  aqui Fonte: NATURE BIOTECHNOLOGY VOLUME 35 NUMBER 5 MAY 2017 399…

Drug pipeline: 1Q17

The first quarter saw a rash of approvals. Among the most noteworthy small molecules are the first new drug for Parkinson’s disease… Para acessar a publicação na íntegra clique  aqui Fonte: 400 VOLUME 35 NUMBER 5 MAY 2017 NATURE BIOTECHNOLOGY…

Academic partnerships 2016

Preclinical deals between industry and academia dipped in 2016 to 207, down from 236 the year prior, continuing the long slide since Para acessar a publicação na íntegra clique  aqui Fonte: NATURE BIOTECHNOLOGY VOLUME 35 NUMBER 5 MAY 2017 405…